Nodthera

Nodthera company information, Employees & Contact Information

Explore related pages

Nodthera email format Nodthera management contacts

Related company profiles:

NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We’re building a dynamic team of people across our offices in Cambridge, UK and Boston, MA; all united by our shared ambition, enthusiasm, and creativity.

Company Details

Employees
23
Founded
-
Address
Philadelphia, Pennsylvania, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
https://nodthera.com
Keywords
Manager jobs.
HQ
Philadelphia, Pennsylvania
Competitors
COUR Pharma, Excision BioTherapeutics, Gilgamesh Pharmaceuticals, Recludix Pharma, Ascidian Therapeutics, ProFound Therapeutics, Abdera Therapeutics, Fauna Bio, iECURE, inc., BigHat Biosciences.
Looking for a particular Nodthera employee's phone or email?

Nodthera Questions

News

NodThera Announces Appointment of Chris Guiffre, J.D., M.B.A., as Chief Financial Officer - The Manila Times

NodThera Announces Appointment of Chris Guiffre, J.D., M.B.A., as Chief Financial Officer The Manila Times

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor - Yahoo Finance

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor Yahoo Finance

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer - GlobeNewswire

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer GlobeNewswire

The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model - Wiley Online Library

The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model Wiley Online Library

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 - Yahoo! Finance UK

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Yahoo! Finance UK

NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination with a GLP-1 Receptor Agonist - The Manila Times

NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination with a GLP-1 Receptor Agonist The Manila Times

NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1 - GlobeNewswire

NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1 GlobeNewswire

Anti-Inflammatory Effects of NT-0796 Warrant Future Studies in Parkinson Disease, Neurodegeneration - NeurologyLive

Anti-Inflammatory Effects of NT-0796 Warrant Future Studies in Parkinson Disease, Neurodegeneration NeurologyLive

NodThera Parkinson's drug almost matches Wegovy for weight loss in mice, with bonus heart benefits - Fierce Biotech

NodThera Parkinson's drug almost matches Wegovy for weight loss in mice, with bonus heart benefits Fierce Biotech

NodThera’s NT-0796 shows promise in Parkinson’s disease trial - Clinical Trials Arena

NodThera’s NT-0796 shows promise in Parkinson’s disease trial Clinical Trials Arena

NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249 - PR Newswire

NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249 PR Newswire

NodThera says inflammation drug has positive effect in Parkinson’s - BioPharma Dive

NodThera says inflammation drug has positive effect in Parkinson’s BioPharma Dive

NodThera announces positive inflammatory disease data - Labiotech.eu

NodThera announces positive inflammatory disease data Labiotech.eu

NodThera’s NT-0796 Shows Promise as Parkinson Disease Treatment in Phase 1b/2a Trial - NeurologyLive

NodThera’s NT-0796 Shows Promise as Parkinson Disease Treatment in Phase 1b/2a Trial NeurologyLive

NodThera doses first patients in trial of obesity drug NT-0796 - Clinical Trials Arena

NodThera doses first patients in trial of obesity drug NT-0796 Clinical Trials Arena

NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors - Yahoo Finance

NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors Yahoo Finance

NodThera's NLRP3 inhibitor shows further anti-inflammatory promise in phase 1b/2a obesity trial - Fierce Biotech

NodThera's NLRP3 inhibitor shows further anti-inflammatory promise in phase 1b/2a obesity trial Fierce Biotech

NodThera Announces Clinical Progress for Lead NLRP3 Inflammasome Inhibitors and Candidate Selection of Novel Brain-Penetrant Compound - PR Newswire

NodThera Announces Clinical Progress for Lead NLRP3 Inflammasome Inhibitors and Candidate Selection of Novel Brain-Penetrant Compound PR Newswire

NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study - PR Newswire

NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study PR Newswire

Boost For Inflammatory Disease Biotech NodThera With €49M Series B - Labiotech.eu

Boost For Inflammatory Disease Biotech NodThera With €49M Series B Labiotech.eu

Brain penetration profile of Nodthera’s NLRP3 inflammasome inhibitor described - BioWorld MedTech

Brain penetration profile of Nodthera’s NLRP3 inflammasome inhibitor described BioWorld MedTech

Novo, Sanofi lead $55M round for inflammation player NodThera - Fierce Biotech

Novo, Sanofi lead $55M round for inflammation player NodThera Fierce Biotech

Study Finds Parkinson Disease Drug Nearly Matches Wegovy in Weight Loss Effects - Pharmaceutical Executive

Study Finds Parkinson Disease Drug Nearly Matches Wegovy in Weight Loss Effects Pharmaceutical Executive

Nodthera nets $40M to take on chronic inflammation - Fierce Biotech

Nodthera nets $40M to take on chronic inflammation Fierce Biotech

Companies like Nodthera

Fauna Bio logo - Similar company to Nodthera

Fauna Bio

29
Abdera Therapeutics logo - Similar company to Nodthera

Abdera Therapeutics

79
Ascidian Therapeutics logo - Similar company to Nodthera

Ascidian Therapeutics

47
COUR Pharma logo - Similar company to Nodthera

Cour Pharma

80
ProFound Therapeutics logo - Similar company to Nodthera

Profound Therapeutics

45
Excision BioTherapeutics logo - Similar company to Nodthera

Excision Biotherapeu...

35
BigHat Biosciences logo - Similar company to Nodthera

Bighat Biosciences

110
Recludix Pharma logo - Similar company to Nodthera

Recludix Pharma

57
iECURE, inc. logo - Similar company to Nodthera

Iecure, Inc.

33
Gilgamesh Pharmaceuticals logo - Similar company to Nodthera

Gilgamesh Pharmaceut...

34

Top Nodthera Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant